To report the FDA approval of nipocalimab-aahu (IMAAVY) for the treatment of warm autoimmune hemolytic anemia (wAIHA).
Approach:
Approval Details: Nipocalimab-aahu is approved for adults and pediatric patients aged 12 years and older with wAIHA who are currently or were previously treated with corticosteroids.
Mechanism of Action: Nipocalimab binds to and blocks the neonatal Fc receptor, reducing circulating immunoglobulin G antibodies while preserving B-cell function.
Study Design: The approval was based on the phase 2/3 ENERGY trial, a multicenter, randomized, double-blind, placebo-controlled study involving 115 adults with wAIHA.
Endpoints: The primary endpoint was durable hemoglobin response, defined as a hemoglobin concentration of at least 10 g/dL and an increase of at least 2 g/dL from baseline for at least 28 days.
Key Findings:
Approximately 3 times as many participants receiving nipocalimab achieved a durable hemoglobin response compared to those receiving placebo by week 24.
Participants receiving nipocalimab had a mean hemoglobin increase of 1 g/dL at week 1.
At week 24, the mean change in fatigue score was 3.5 points higher with nipocalimab compared to placebo.
Interpretation:
The findings were characterized as descriptive under the prespecified statistical analysis plan.
Limitations:
The study involved a limited sample size of 115 participants.
The findings are based on a specific patient population with wAIHA.
Conclusion:
Nipocalimab is the first therapy approved specifically for wAIHA, demonstrating efficacy in increasing hemoglobin levels and reducing fatigue.
